AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10802278 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinylestradiol:norethindrone acetate (20:1000 and 15:1000 µg daily over 4 months)
Number of subjects: 169
Study 10802278 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol:norethindrone acetate (20:1000 µg daily over 12 months)
Number of subjects: 169
Study 10802278 — intervention group
Group type: COMPARATOR
Intervention: Control group (sexually active women from earlier study)
Number of subjects: 169
Study 8644693 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium supplementation (3.3‐3.5 mumol as chromium chloride or chromium picolinate)
Number of subjects: 36
Study 8644693 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation
Number of subjects: 36
Study 8644693 — intervention group
Group type: COMPARATOR
Intervention: Chromium chloride or placebo
Number of subjects: 36
Study 8644693 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 36
Study 2062620 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC vaccine (3-dose regimen, first dose between 6 weeks and 6 months, minimum interval of 1 month between doses, third dose by 1 year of age)
Number of subjects: 61080
Study 2062620 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC vaccine (3-dose regimen)
Number of subjects: 61080
Study 2062620 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC vaccine (1 dose)
Number of subjects: 61080
Study 2062620 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC vaccine
Number of subjects: 61080
Study 6339154 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (standardized exercise programme, 1 hour twice weekly for 8 months)
Number of subjects: 31
Study 6339154 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 31
Study 6339154 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (standardized exercise programme)
Number of subjects: 31
Study 31706382 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia diagnosis
Number of subjects: 252
Study 31706382 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisocial traits/behaviors
Number of subjects: 252
Study 31706382 — intervention group
Group type: EXPERIMENTAL
Intervention: White juveniles with antisocial traits
Number of subjects: 252
Study 29353508 — intervention group
Group type: EXPERIMENTAL
Intervention: Aided communication
Number of subjects: 152
Study 29353508 — intervention group
Group type: COMPARATOR
Intervention: Natural speech (reference group)
Number of subjects: 152
Study 26367270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention (MBI) for eight weeks
Number of subjects: 144
Study 22429361 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRIOSE® 10 g/day for 14 days
Number of subjects: 88
Study 22429361 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRIOSE® 15 g/day for 14 days
Number of subjects: 88
Study 22429361 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRIOSE® 20 g/day for 14 days
Number of subjects: 88
Study 22429361 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRIOSE® 8 g/day for 14 days
Number of subjects: 88
Study 22429361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 20463176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate-guided therapy (treatment guided by lactate levels aiming to decrease lactate by 20% or more per 2 hours for the initial 8 hours)
Number of subjects: 348
Study 20463176 — intervention group
Group type: COMPARATOR
Intervention: Control group (no knowledge of lactate levels during the initial treatment period)
Number of subjects: 348
Study 20463176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate-guided therapy
Number of subjects: 348
Study 19301628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand acupuncture treatment
Number of subjects: 52
Study 19301628 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 16306031 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin extended-release (ER), 1000 mg once daily
Number of subjects: 14
Study 16306031 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin immediate-release (IR), 500 mg bid
Number of subjects: 14
Study 12410855 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (up to 40 mg/day)
Number of subjects: 45
Study 12410855 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (up to 32 mg/day)
Number of subjects: 45
Study 12410855 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (lisinopril up to 20 mg/day plus candesartan up to 16 mg/day)
Number of subjects: 45
Study 12410855 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy vs Candesartan alone
Number of subjects: 45
Study 12410855 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy vs Lisinopril only
Number of subjects: 45
Study 10561307 — intervention group
Group type: EXPERIMENTAL
Intervention: Eniluracil 10 mg/m(2) twice daily for 3 days before surgery
Number of subjects: 20
Study 10561307 — intervention group
Group type: EXPERIMENTAL
Intervention: Eniluracil treatment
Number of subjects: 20
Study 10561307 — intervention group
Group type: COMPARATOR
Intervention: Untreated control patients
Number of subjects: 20
Study 8659579 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram-positive bacteria isolated from patients with confirmed growth (274 patients, 94.2%)
Number of subjects: 420
Study 8659579 — intervention group
Group type: EXPERIMENTAL
Intervention: All gram-positive isolates tested
Number of subjects: 420
Study 8659579 — intervention group
Group type: EXPERIMENTAL
Intervention: Seventeen gram-negative isolates (89%)
Number of subjects: 420
Study 8659579 — intervention group
Group type: EXPERIMENTAL
Intervention: Two gram-negative isolates (11%)
Number of subjects: 420
Study 8659579 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior chamber or secondary IOL implantations
Number of subjects: 420
Study 8659579 — intervention group
Group type: COMPARATOR
Intervention: Posterior chamber IOL implantations or primary cataract extractions
Number of subjects: 420
Study 1810355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ames Multistix 10 dipstick
Number of subjects: 615
Study 1810355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ames Multistix 10 dipstick tests for nitrite and leucocyte esterase
Number of subjects: 615
Study 1810355 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflectance meter with Ames Multistix 10
Number of subjects: 615
Study 1810355 — intervention group
Group type: COMPARATOR
Intervention: Common urinary symptoms (including incontinence)
Number of subjects: 615
Study 6382999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 3806
Study 30395812 — intervention group
Group type: EXPERIMENTAL
Intervention: RPC4046 180 mg
Number of subjects: 99
Study 30395812 — intervention group
Group type: EXPERIMENTAL
Intervention: RPC4046 360 mg
Number of subjects: 99
Study 30395812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 29569535 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian diet without supplementation (Veg+Pla, n=15)
Number of subjects: 40
Study 29569535 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet combined with daily β-alanine (0.8-0.4 g/d) and creatine supplementation (1 g creatine monohydrate/d) (Veg+Suppl, n=15)
Number of subjects: 40
Study 29569535 — intervention group
Group type: COMPARATOR
Intervention: Continued omnivorous diet (control, n=10)
Number of subjects: 40
Study 26078286 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine-supplemented parenteral nutrition (Gln-PN)
Number of subjects: 0
Study 24794283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral triamcinolone acetonide (TA)
Number of subjects: 77
Study 24794283 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (Control)
Number of subjects: 77
Study 22270500 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG) 3350 for 3 days outpatient
Number of subjects: 79
Study 22270500 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk and molasses enema in the ED
Number of subjects: 79
Study 22270500 — intervention group
Group type: COMPARATOR
Intervention: Control group (PEG 3350)
Number of subjects: 79
Study 19417589 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabadone (amino acid preparation)
Number of subjects: 18
Study 19417589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17630491 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous suturing of the subcutaneous fat tissue
Number of subjects: 415
Study 17630491 — intervention group
Group type: COMPARATOR
Intervention: No subcutaneous suturing of the subcutaneous fat tissue
Number of subjects: 415
Study 18162241 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (types 6, 11, 16, 18)
Number of subjects: 0
Study 14999536 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (50 mg kg(‐1) intravenously for 3 days)
Number of subjects: 40
Study 14999536 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 10660922 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus acupressure training and treatment
Number of subjects: 17
Study 10660922 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 17
Study 9120912 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (BCG) therapy with isoniazid (300 mg daily)
Number of subjects: 0
Study 9120912 — intervention group
Group type: COMPARATOR
Intervention: Intravesical bacillus Calmette-Guerin (BCG) therapy without isoniazid
Number of subjects: 0
Study 8251274 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 12.5 mg with adrenaline 25 micrograms and sufentanil 10 micrograms (Group A)
Number of subjects: 50
Study 8251274 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 12.5 mg with adrenaline 25 micrograms and clonidine 30 micrograms (Group B)
Number of subjects: 50
Study 2418328 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin chemotherapy (60 mg/m2, i.v., given every 3 weeks, up to a maximum dose of 550 mg/m2)
Number of subjects: 66
Study 2418328 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 66
Study 2418328 — intervention group
Group type: COMPARATOR
Intervention: Surgically treated patients
Number of subjects: 66
Study 11413601 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg intravenous erythromycin
Number of subjects: 15
Study 31921879 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 g pistachios
Number of subjects: 0
Study 31921879 — intervention group
Group type: COMPARATOR
Intervention: 100 g whole-wheat bread (WWB)
Number of subjects: 0
Study 29232645 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol (experimental group)
Number of subjects: 0
Study 29232645 — intervention group
Group type: COMPARATOR
Intervention: Hospital standard (control group)
Number of subjects: 0
Study 26474232 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates + physical therapy (PPT)
Number of subjects: 101
Study 26474232 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT) only
Number of subjects: 101
Study 24913169 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose primaquine treatment
Number of subjects: 0
Study 24913169 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22367193 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg
Number of subjects: 58
Study 22367193 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 58
Study 22367193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 20163882 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic examination after adenoidectomy
Number of subjects: 312
Study 20163882 — intervention group
Group type: COMPARATOR
Intervention: No endoscopic examination after adenoidectomy
Number of subjects: 312
Study 18441625 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi sensory behavior therapy (MSBT) with standard psychiatric inpatient care
Number of subjects: 24
Study 16055834 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis card offering 24-h crisis telephone consultation
Number of subjects: 0
Study 12168731 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot goserelin (Group 1)
Number of subjects: 459
Study 12168731 — intervention group
Group type: COMPARATOR
Intervention: Daily leuprolide acetate (Group 2)
Number of subjects: 459
Study 10442493 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice
Number of subjects: 15
Study 10442493 — intervention group
Group type: COMPARATOR
Intervention: Synthetic orange drink
Number of subjects: 15
Study 7874586 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 142
Study 7874586 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 142
Study 2230623 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (AP) - single oral dose of 1, 2, 3, and 6 g
Number of subjects: 106
Study 2230623 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (AP) - daily doses of 0.12-24 g per kg body weight for six months
Number of subjects: 106
Study 2230623 — intervention group
Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (AP) - direct assay of anti-bacterial activity in water solution (25,000 mg per litre)
Number of subjects: 106
Study 323811 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TM-SM)
Number of subjects: 20
Study 323811 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 20
Study 31662863 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (LAN) 90 mg
Number of subjects: 24
Study 31662863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30053840 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 555
Study 30053840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health education)
Number of subjects: 555
Study 27191767 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced formulation of megestrol acetate containing nanocrystals (test formulation)
Number of subjects: 80
Study 27191767 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation of megestrol acetate (reference formulation)
Number of subjects: 80
Study 27191767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference formulations
Number of subjects: 80
Study 24877242 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-G SF-EUS-FNA
Number of subjects: 120
Study 24877242 — intervention group
Group type: COMPARATOR
Intervention: 25-G SF-EUS-FNA
Number of subjects: 120
Study 23290218 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive aortic valve replacement
Number of subjects: 39
Study 23290218 — intervention group
Group type: COMPARATOR
Intervention: Conventional aortic valve replacement
Number of subjects: 39
Study 20563593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative staining with methylene blue (Group 1)
Number of subjects: 30
Study 20563593 — intervention group
Group type: EXPERIMENTAL
Intervention: No intraoperative staining (Group 2)
Number of subjects: 30
Study 20563593 — intervention group
Group type: COMPARATOR
Intervention: Control group (experienced surgeons)
Number of subjects: 30
Study 17386196 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable NIOX MINO monitor
Number of subjects: 0
Study 17386196 — intervention group
Group type: COMPARATOR
Intervention: N‐6008 chemiluminescence analyzer
Number of subjects: 0
Study 16779075 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic templates
Number of subjects: 0
Study 16779075 — intervention group
Group type: COMPARATOR
Intervention: Dictation services
Number of subjects: 0
Study 12559802 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIV-T blended and filled at Medeva
Number of subjects: 225
Study 12559802 — intervention group
Group type: COMPARATOR
Intervention: CAIV-T blended and filled at Aviron-PA
Number of subjects: 225
Study 10802000 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual nitroglycerin (300 microg)
Number of subjects: 71
Study 10802000 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose intravenous isoproterenol (mean infusion rate 1.3 +/- 0.5 microg/min)
Number of subjects: 71
Study 10802000 — intervention group
Group type: COMPARATOR
Intervention: sublingual nitroglycerin test
Number of subjects: 71
Study 10802000 — intervention group
Group type: COMPARATOR
Intervention: low-dose isoproterenol test
Number of subjects: 71
Study 8895233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (bolus at 0.1 mg/kg/5 min followed by an infusion of 7 micrograms/kg/min)
Number of subjects: 11
Study 8895233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 11
Study 8895233 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 11
Study 2072513 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with 1:100,000 clonidine (n = 7)
Number of subjects: 34
Study 2072513 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine (n = 8)
Number of subjects: 34
Study 2072513 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with 1:200,000 clonidine (n = 6)
Number of subjects: 34
Study 2072513 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with 1:200,000 epinephrine (n = 13)
Number of subjects: 34
Study 6309710 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron irradiation twice weekly
Number of subjects: 142
Study 6309710 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron irradiation four times per week
Number of subjects: 142
Study 6309710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-schedule irradiation (two neutron and three photon fractions per week)
Number of subjects: 142
Study 6309710 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (surgery, photon irradiation, or combined surgery and photon irradiation)
Number of subjects: 142
Study 30754039 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 96
Study 30754039 — intervention group
Group type: COMPARATOR
Intervention: Weight Stability (WS)
Number of subjects: 96
Study 29431546 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week training protocol with traditional multijoint power resistance exercises, Olympic-style lifts, plyometric drills, and speed work (4 times per week)
Number of subjects: 22
Study 29431546 — intervention group
Group type: COMPARATOR
Intervention: Cessation of training (control group)
Number of subjects: 22
Study 29431546 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week training protocol (experimental group)
Number of subjects: 22
Study 26792218 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent twice‐daily RT (45 Gy in 30 twice‐daily fractions over 3 weeks)
Number of subjects: 447
Study 26792218 — intervention group
Group type: COMPARATOR
Intervention: Concurrent once‐daily RT (66 Gy in 33 once‐daily fractions over 6.5 weeks)
Number of subjects: 447
Study 26792218 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 447
Study 24918371 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 181
Study 24918371 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP plus weight-loss intervention
Number of subjects: 181
Study 24918371 — intervention group
Group type: COMPARATOR
Intervention: CPAP alone
Number of subjects: 181
Study 24918371 — intervention group
Group type: EXPERIMENTAL
Intervention: All three groups (CPAP, weight loss, CPAP plus weight loss)
Number of subjects: 181
Study 24918371 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions (CPAP plus weight loss)
Number of subjects: 181
Study 24918371 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 181
Study 21820142 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 215
Study 21820142 — intervention group
Group type: COMPARATOR
Intervention: Non-CPAP group
Number of subjects: 215
Study 19892345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 100
Study 19892345 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 100
Study 18173141 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaokang Zhongzi Recipe (XZR)
Number of subjects: 110
Study 18173141 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 110
Study 16250037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine plus rhIL-12 (500 ng/kg)
Number of subjects: 15
Study 16250037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine plus rhIL-12 (200 ng/kg)
Number of subjects: 15
Study 16250037 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine alone
Number of subjects: 15
Study 11916898 — intervention group
Group type: EXPERIMENTAL
Intervention: Snowboarding
Number of subjects: 674
Study 11916898 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpine skiing
Number of subjects: 674
Study 11916898 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <16 years
Number of subjects: 674
Study 11916898 — intervention group
Group type: EXPERIMENTAL
Intervention: More than five days of experience in the current season
Number of subjects: 674
Study 11916898 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one week of experience in total
Number of subjects: 674
Study 11916898 — intervention group
Group type: COMPARATOR
Intervention: Control group (uninjured individuals)
Number of subjects: 674
Study 9766290 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT) and dialogue (10 minutes of TT and 20 minutes of dialogue)
Number of subjects: 29
Study 9766290 — intervention group
Group type: COMPARATOR
Intervention: Quiet time and dialogue (10 minutes of quiet time and 20 minutes of dialogue)
Number of subjects: 29
Study 7877288 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with highly agreed intervals
Number of subjects: 30
Study 7877288 — intervention group
Group type: COMPARATOR
Intervention: Training with poorly agreed intervals
Number of subjects: 30
Study 7877288 — intervention group
Group type: COMPARATOR
Intervention: Training with randomly selected intervals
Number of subjects: 30